26 May PHENOTYPECA SUCCESSFULLY COMPLETE FIRST QUARTER OF INNOVATE UK PROJECT WITH INVIZIUS AND CPI
BioCity client company Phenotypeca, are delighted to announce a positive first-quarter result in the Innovate UK funded project, developing next-generation baker’s yeast production strains for BioCity, Glasgow based Invizius’ novel H-Guard coating for dialysis membranes. These will be capable of preventing, at source, the blood’s foreign body reactions, and therefore improving longterm dialysis outcomes for patients.
In early December 2019, Phenotypeca, Invizius and CPI were awarded an Innovate UK Smart Grant “Development of second-generation S. cerevisiae hosts for enhanced protein yield and quality” to apply technology proven for the cGMP manufacture of biopharmaceuticals to the production of Invizius’ H-Guard product. Using genetically diverse strains of baker’s yeast, Saccharomyces cerevisiae, Phenotypeca will screen a population of up to a billion progeny to identify cells with improved properties for H-Guard production during yeast fermentations performed at CPI.
“We have made a great start”, says Keith Williams, Managing Director of Phenotypeca, who are leading the project, “It’s been exceptional to bring together such a unique combination of world-leading scientists to improve our manufacturing technology in this way and in the UK, all of which has been made possible by Innovate UK’s support now and during previous infrastructure investments at CPI. We look forward to pressing on with the project once we are able to get back into the labs soon!”